title: [Gastroduodenal injury in patients with low-dose enteric coated aspirin treatment].
abstract: OBJECTIVE
  Low-dose aspirin therapy is widely used to prevent cardiovascular thrombotic events. However, the safety of low-dose aspirin therapy in the gastrointestinal tract is uncertain. Our aim was to evaluate endoscopic findings in patients taking low-dose aspirin.
  
  
  METHODS
  Sixty-two patients who received 100 mg enteric coated aspirin daily more than 30 days were included in this study. Patients' medical records and endoscopic data were reviewed retrospectively. As controls, 70 of age- and gender-matched patients who received an endoscopy without gastrointestinal symptoms were employed.
  
  
  RESULTS
  The overall prevalence of gastroduodenal mucosal injury was higher in the aspirin group than in the control group. Erosive gastritis was noted more frequently in the aspirin group than in the control group. However, the prevalence of ulcer was not different between the aspirin group and the control group.
  
  
  CONCLUSIONS
  Patients treated with low-dose aspirin therapy are more likely to have endoscopic evidence of mucosal damage. Our study suggests that even a low-dose aspirin therapy can induce a gastroduodenal mucosal injury. In the future, a prospective randomized control study is needed.
authors.affiliation: Department of Internal Medicine, Hanyang University College of Medicine, Gyeonggi, Korea.
authors.forename: Hang Lak
authors.initials: HL
authors.lastname: Lee
authors.forename: Dong Soo
authors.initials: DS
authors.lastname: Han
authors.forename: Jin Bae
authors.initials: JB
authors.lastname: Kim
authors.forename: Joon Yong
authors.initials: JY
authors.lastname: Park
authors.forename: Joo Hyun
authors.initials: JH
authors.lastname: Sohn
authors.forename: Joon Soo
authors.initials: JS
authors.lastname: Hahm
authors.forename: You Hern
authors.initials: YH
authors.lastname: Ahn
mesh_terms: D000368:Aged; D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000517:prevention & control; D004941:Esophagitis / Q000139:chemically induced; D005260:Female; D005756:Gastritis / Q000139:chemically induced; D005767:Gastrointestinal Diseases / Q000139:chemically induced*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D013608:Tablets, Enteric-Coated / Q000009:adverse effects
chemical_list: D010975:Platelet Aggregation Inhibitors; D013608:Tablets, Enteric-Coated; D001241:Aspirin